Although some success was achieved for treatment of ovarian cancer patients with the PARP-1 inhibitor olaparib, resistance to the drug has limited its therapeutic effectiveness (Murata et al., 2016), leaving researchers to continue exploring and developing new and better cancer therapies focused on PARP inhibitors targeting each member of the family and optimal co-treatment strategies of these compounds with other anti-cancer agents. This evidence concerns the gene PARP1 and ovarian cancer.